Recombinant Factor VIIa in the Treatment of Bleeding

American Journal of Clinical Pathology

Volumn 121, Issue 1, 2004, Pages 124-137

  Midathada, Madhu V ^a,c   Mehta, Paulette ^a,c   Waner, Milton ^b,d   Fink, Louis M ^b,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^d ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

Drug induced coagulopathies; Factor VII deficiency; Liver failure; Platelet disorders; Postsurgical bleeding; Posttrauma bleeding; Recombinant factor VIIa; Von Willebrand disease

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 COMPLEX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; TIROFIBAN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; BLEEDING DISORDER; BLOOD CLOTTING; BRAIN INFARCTION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG INDICATION; GANGRENE; GLANZMANN DISEASE; HEMOPHILIA; HEMOSTASIS; HUMAN; KIDNEY FAILURE; LIVER DISEASE; PREGNANCY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS; TRANSPLANTATION; VON WILLEBRAND DISEASE;

EID: 0347130903     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/D0G0C96V05CJ5B4J     Document Type: Review

References (144)

1. Astermark J, Ekman M, Berntorp E. Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors. Br J Haematol. 2002;119:342-347.
2. Carr ME Jr, Loughran TP, Cardea JA, et al. Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor. Int J Hematol. 2002;75:95-99.
3. Chuansumrit A, Chantarojanasiri T, Isarangkura P, et al. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S101-S105.
4. Conesa V, Mompel A, Lopez F, et al. Effective treatment with recombinant factor VIIa of severe bleeding due to acquired factor VIII inhibitor and acquired thrombocytopathy [letter]. Am J Hematol. 2002;70:329-330.
5. Faradji A, Bonnomet F, Lecocq J, et al. Knee joint arthroplasty in a patient with haemophilia A and high inhibitor titre using recombinant factor VIIa (NovoSeven): a new case report and review of the literature. Haemophilia. 2001;7:321-326.
6. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood. 2002;99:175-179.
7. McPherson J, Teague L, Lloyd J, et al. Experience with recombinant factor VIIa in Australia and New Zealand. Haemostasis. 1996;26(suppl 1):109-117.
8. O'Connell N, Chen J, Byrne M, et al. Massive pseudotumour resection with recombinant factor VIIa (NovoSeven) cover. Br J Haematol. 2002;116:645-648.
9. Puetz JJ, Bouhasin JD. Use of recombinant factor viIa to control bleeding in an adolescent male with severe hemophilia A, HIV thrombocytopenia, hepatitis C, and end-stage liver disease. Am J Hospice Palliative Care. 2002;19:277-282.
10. Divanon F, Hecquard C, Borel-Derlon A. Experience with use of recombinant activated factor VII. J Clin Pharm Ther. 2002;27:133-138.
11. Rao LV, Rapaport SI. Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood. 1990;75:1069-1073.
12. Hedner U, Glazer S, Pingel K, et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet. 1988;2:1193.
13. Parameswaran, Shapiro AD, Gill JC, et al. Dose effect and efficacy of recombinant factor VIIa (rFVIIa) in the treatment of hemophilia patients with inhibitors: analysis from the Hemophilia Research Society (HRS) Registry [abstract]. Blood. 2002;100:22A.
14. Sichler K, Banner DW, D'Arev A, et al. Crystal structures of uninhibited factor VIIa link its cofactor and substrate-assisted activation to specific interactions. J Mol Biol. 2002;322:591-603.
15. Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S107-S111.
16. Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost. 2003;1:1138-1139.
17. Heuer L, Blumenberg D. Recombinant factor VIIa (NovoSeven): a review of current and possible future indications [in German]. Anaesthesist. 2002;51:388-399.
18. Rapaport SI. Coagulation problems in liver disease. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S69-S74.
19. Bolan CD, Klein HG. Transfusion medicine and pharmacologic aspects of hemostasis. In: Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. Philadelphia, PA: Saunders; 2002:398-399.
20. Penner JA. Management of haemophilia in patients with high-titre inhibitors: focus on the evolution of activated prothrombin complex concentrate AUTOPLEX T. Haemophilia. 1999;5(suppl 3):1-9.
21. Wilde JT. Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors. Pathophysiol Haemost Thromb. 2002;32(suppl 1):9-12.
22. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002;8:83-90.
23. Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia. 1999;5(suppl 3):11-17.
24. Kaul VV, Munoz SJ. Coagulopathy of liver disease. Curr Treat Options Gastroenterol. 2000;3:433-438.
25. Schreiber MA, Holcomb JB, Hedner U, et al. The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. J Trauma. 2002;53:252-259.
26. Lynn M, Jerokhimov I, Jewelewicz D, et al. Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: a pilot study. J Trauma. 2002;52:703-707.
27. Jeroukhimov I, Jewelewicz D, Zaias J, et al. Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury. J Trauma. 2002;53:1053-1057.
28. Lisman T, Leebeek FW, Meijer K, et al. Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology. 2002;35:616-621.
29. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology. 1997;113:1930-1937.
30. Ejlersen E, Melsen T, Ingerslev J, et al. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol. 2001;36:1081-1085.
31. Chuansumrit A, Treepongkaruna S, Phuapradit P. Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases. Thromb Haemost. 2001;85:748-749.
32. Berthier AM, Guillygomarc'h A, Messner M, et al. Use of recombinant factor VIIa to treat persistent bleeding following dental extractions in two cirrhotic patients. Vox Sang. 2002;82:119-121.
33. Jeffers L, Chalasani N, Balart L, et al. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology. 2002;123:118-126.
34. Kositchaiwat C, Chuansumrit A. Experiences with recombinant factor VIIa for the prevention of bleeding in patients with chronic liver disease undergoing percutaneous liver biopsies and endoscopic retrograde cholangiopancreatography (ERCP) [letter]. Thromb Haemost. 2001;86:1125-1126.
35. Chal SJ, Macik BG. Activated recombinant factor VIIa (rFVIIa) for the reversal of hepatic and warfarin induced coagulopathy prior to invasive procedures [abstract]. J Thromb Haemost. 2003;1(suppl 1).
36. Lyengar S, Duncan A, Martinez E, et al. Single-dose use of recombinant factor VIIa (Novoseven) for correction of hepatic induced coagulopathies prior to minor, invasive procedures [abstract]. J Thromb Haemost. 2003;1(suppl 1).
37. Kalicinski P, Kaminski A, Drewniak T, et al. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transplant Proc. 1999;31:378-379.
38. Jureczko L, Trzebicki J, Zawadzki A, et al. Application of recombinant activated factor VII for treatment of impaired haemostasis during liver transplantation in recipients with Wilson's disease: a report of two cases. Ann Transplant. 2002;7:52-54.
39. Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl. 2003;9:138-143.
40. Hendriks HG, Meijer K, de Wolf JT, et al. Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis. 2002;13:309-313.
41. Berntorp E, Stigendal L, Lethagen S, et al. NovoSeven in warfarin-treated patients. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S113-S115.
42. Berntorp E. Recombinant FVIIa in the treatment of warfarin bleeding. Semin Thromb Hemost. 2000;26:433-435.
43. Diness V, Lund-Hansen T, Hedner U. Effect of recombinant human FVIIA on warfarin-induced bleeding in rats. Thromb Res. 1990;59:921-929.
44. Girard P, Nony P, Erhardtsen E, et al. Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. Thromb Haemost. 1998;80:109-113.
45. Muleo G, Santoro R, Iannaccaro, PG, et al. Small doses of recombinant factor VIIa in acquired deficiencies of vitamin K dependent factors [letter]. Blood Coagul Fibrinolysis. 1999;10:521-522.
46. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med. 2002;137:884-888.
47. Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Med Sci Monit. 2002;8:CS98-CS 100.
48. Lisman T, Moschatsis S, Adelmeijer J, et al. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood. 2003;101:1864-1870.
49. Stepinska J, Banaszewski M, Konopka A, et al. Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/ IIIa-inhibitor tirofiban [letter]. Thromb Haemost. 2002;87:355-356.
50. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106:2550-2554.
51. Kessler C. Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII? Intensive Care Med. 2002;28(suppl 2):S228-S234.
52. Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis. 1996;26(suppl 1):159-164.
53. Laurian Y. Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa? Pathophysiol Haemost Thromb. 2002;32(suppl 1):37-40.
54. Kjalke M, Johannessen M, Hedner U. Effect of recombinant factor VIIa (Novoseven) on thrombocytopenia-like conditions in vitro. Semin Hematol. 2001;38(4 suppl 12):15-20.
55. Chuansumrit A, Suwannuraks M, Sri-Udomporn N, et al. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis. 2003;14:187-190.
56. Chuansumrit A, Sangkapreecha C, Hathirat P. Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa [letter]. Thromb Haemost. 1999;82:1778.
57. Ancliff PF, Liesner R, Khair K, et al. The use of recombinant factor VIIa in a patient with severe Glanzmann's thrombasthenia to facilitate insertion of a Port-a-Cath [letter]. Blood Coagul Fibrinolysis. 1999;10:447-448.
58. Poon MC, d'Oiron R, Hann I, et al. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol. 2001;38(4 suppl 12):21-25.
59. Patel RK, Savidge GF, Rangarajan S. Use of recombinant factor VIIa for post-operative haemorrhage in a patient with Glanzmann's thrombasthenia and human leucocyte antigen antibodies. Br J Haematol. 2001;114:245-246.
60. Poon MC, d'Oiron R. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S55-S68.
61. van Buuren HR, Wielenga JJ. Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia. Dig Dis Sci. 2002;47:2134-2136.
62. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa [letter]. Thromb Haemost. 1998;80:352.
63. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa [letter]. Thromb Haemost. 1996;75:981-982.
64. Poon MC, Demers C, Jobin F, et al. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood. 1999;94:3951-3953.
65. d'Oiron R, Menart C, Trzeciak MC, et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost. 2000;83:644-647.
66. Robinson KL, Savoia H, Street AM. Thrombotic complications in two patients receiving Novoseven. Haemophilia. 2000;6:343-368.
67. Gerotziafas GT, Zervas C, Gavrielidis G, et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol. 2002;69:219-222.
68. Meijer K, Sieders E, Slooff MJ, et al. Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII [letter]. Thromb Haemost. 1998;80:204-205.
69. Majumdar G, Savidge GF. Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors. Blood Coagul Fibrinolysis. 1993;4:1031-1033.
70. Papatheodoridis GV, Chung S, Keshav S, et al. Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis. J Hepatol. 1999;31:747-750.
71. Monroe DM, Hoffman M, Allen GA, et al. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost. 2000;26:373-377.
72. Moisescu E, Ardelean L, Simion I, et al. Recombinant factor VIIa treatment of bleeding associated with acute renal failure [letter]. Blood Coagul Fibrinolysis. 2000;11:575-577.
73. Revesz T, Arets B, Bierings M, et al. Recombinant factor VIIa in severe uremic bleeding [letter]. Thromb Haemost. 1998;80:353.
74. Mariani G, Testa MG, Paolantonio T, et al. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang. 1999;77:131-136.
75. Hunault M, Bauer KA. Recombinant factor VIIa for the treatment of congenital factor VII deficiency. Semin Thromb Hemost. 2000;26:401-405.
76. Jimenez-Yuste V, Villar A, Morado M, et al. Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency. Haemophilia. 2000;6:588-590.
77. Wong WY, Huang WC, Miller R, et al. Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency. Haemophilia. 2000;6:50-54.
78. Billio A, Pescosta N, Rosanelli C, et al. Successful short-term oral surgery prophylaxis with rFVIIa in severe congenital factor VII deficiency [letter]. Blood Coagul Fibrinolysis. 1997;8:249-250.
79. White B, O'Connor H, Smith OP. Successful use of recombinant VIIa (Novoseven) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency. Blood Coagul Fibrinolysis. 2000;11:155-157.
80. Berrettini M, Mariani G, Schiavoni M, et al. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica. 2001;86:640-645.
81. Billon S, Le Niger C, Escoffre-Barbe M, et al. The use of recombinant factor VIIa (NovoSeven) in a patient with a factor XI deficiency and a circulating anticoagulant. Blood Coagul Fibrinolysis. 2001;12:551-553.
82. Ciavarella N, Schiavoni M, Valenzano E, et al. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis. 1996;26(suppl 1):150-154.
83. Grossmann RE, Geisen U, Schwenders S, et al. Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor [letter]. Thromb Haemost. 2000;83:633-634.
84. Meijer K, Peters FT, van der Meer J. Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. Blood Coagul Fibrinolysis. 2001;12:211-213.
85. Friederich PW, Wever PC, Briet E, et al. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol. 2001;66:292-294.
86. Perez-Montes R, Arce O, Bermudez A, et al. Recombinant factor VIIa as a hemostatic agent in acquired von Willebrand disease [abstract]. J Thromb Haemost. 2003;1(suppl 1).
87. Smaradottir A, Bona R, Fritts L. A case of acquired von Willebrand syndrome successfully treated with recombinant factor VIIa during thyroidectomy [abstract]. J Thromb Haemost. 2003;1(suppl).
88. Boggio L, Green D. Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency. Br J Haematol. 2001;112:1074-1075.
89. Blatt J, Gold SH, Wiley JM, et al. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant. 2001;28:405-407.
90. Perez-Montes R, Bermudez A, Arce O, et al. Successful use of recombinant FVIIa (Novoseven) for severe bleeding in a patient undergoing bone marrow transplantation refractory to standard hemostatic support. J Thromb Haemost. 2003;1(suppl 1):1128.
91. Hendriks HG, Meijer K, de Wolf JT, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation. 2001;71:402-405.
92. Meijer K, Hendriks HG, De Wolf JT, et al. Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis. Blood Coagul Fibrinolysis. 2003;14:169-174.
93. Eskandari N, Feldman N, Greenspoon JS. Factor VII deficiency in pregnancy treated with recombinant factor VIIa. Obstet Gynecol. 2002;99(5 pt 2):935-937.
94. Zupancic Salek, S, Sokolic V, Viskovic T, et al. Successful use of recombinant factor VIIa for massive bleeding after caesarean section due to HELLP syndrome. Acta Haematol. 2002;108:162-163.
95. Moscardo F, Perez F, de la Rubia J, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol. 2001;114:174-176.
96. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb. 2002;32(suppl 1):41-46.
97. Kessler C, Szurlej D, Von Heymann C. Management of refractory postoperative cardiac bleeding with recombinant factor VIIa (rFVIIa): cases reported to the hemostasis.com registry [abstract]. J Thromb Haemost. 2003;1(suppl 1).
98. Tobias JD, Berkenbosch JW, Muruve NA, et al. Correction of a coagulopathy using recombinant factor VII before removal of an intra-aortic balloon pump. J Cardiothorac Vasc Anesth. 2002;16:612-614.
99. von Heymann C, Hotz H, Konertz W, et al. Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2002;16:615-616.
100. Kastrup M, von Heymann C, Hotz H, et al. Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta. Ann Thorac Surg. 2002;74:910-912.
101. Hendriks HG, van der Maaten JM, de Wolf J, et al. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg. 2001;93:287-289.
102. del Pozo Pozo AI, Jimenez-Yuste V, Villar A, et al. Successful thyroidectomy in a patient with Hermansky-Pudlak syndrome treated with recombinant activated factor VII and platelet concentrates. Blood Coagul Fibrinolysis. 2002;13:551-553.
103. Tobias JD. Synthetic factor VIIa to treat dilutional coagulopathy during posterior spinal fusion in two children. Anesthesiology. 2002;96:1522-1525.
104. Sanchez MP, Nebreda J B, Garcia VC. Recombinant activated factor VII prevents bleeding during a surgical procedure in a patient with uncontrollable rectal hemorrhage [letter]. Am J Gastroenterol. 2002;97:1266-1267.
105. White B, McHale J, Ravi N. Successful use of recombinant FVIIa (Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage [letter]. Br J Haematol. 1999;107:677-678.
106. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial [published correction appears in Lancet. 2003;361:1138]. Lancet. 2003;361:201-205.
107. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial [published correction appears in Lancet. 2003;361:1138]. Lancet. 2003;361:201-205.
108. Slappendel R, Huvers FC, Benraad B, et al. Use of recombinant factor VIIa (NovoSeven) to reduce postoperative bleeding after total hip arthroplasty in a patient with cirrhosis and thrombocytopenia. Anesthesiology. 2002;96:1525-1527.
109. Chuansumrit A, Nuntnarumit P, Okascharoen C, et al. The use of recombinant activated factor VII to control bleeding in a preterm infant undergoing exploratory laparotomy. Pediatrics. 2002;110(1pt 1):169-171.
110. Park P, Fewel MF, Thompson BG, et al. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery. 2003;53:34-39.
111. Gerlach R, Scharrer I, Raabe A, et al. The administration of recombinant coagulation factor VIIa (rFVIIa) during neurosurgical procedures [abstract]. J Thromb Haemost. 2003;1(suppl 1).
112. Kenet G, Walden R, Eldad A, et al. Treatment of traumatic bleeding with recombinant factor VIIa [letter]. Lancet. 1999;354:1879.
113. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma. 2001;51:431-439.
114. Pickard JD, Kirkpatrick PJ, Melsen T, et al. Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S117-S120.
115. Rice KM, Savidge GF. NovoSeven (recombinant factor VIIa) in central nervous systems bleeds. Haemostasis. 1996;26(suppl 1):131-134.
116. Kamphuisen PW, van den Akker JM, Kaasjager KA, et al. Control of life-threatening pulmonary bleeding with activated recombinant factor VII [letter]. Am J Med. 2002;112:332-333.
117. Meijer K, de Graaff WE, Daenen SM, et al. Successful treatment of massive hemoptysis in acute leukemia with recombinant factor VIIa [letter]. Arch Intern Med. 2000;160:2216-2217.
118. Svartholm E, Annerhagen V, Lanne T. Treatment of bleeding in severe necrotizing pancreatitis with recombinant factor VIIa [letter]. Anesthesiology. 2002;96:1528.
119. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost. 2000;26:385-391.
120. Erhardtsen E, Nilsson P, Johannessen M, et al. Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects. J Clin Pharmacol. 2001;41:880-885.
121. Seremetis S. Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors. Blood Coagul Fibrinolysis. 2003;14(suppl 1):S29-S30.
122. Shirahata A, Kamiya T, Takamatsu J, et al. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors. Int J Hematol. 2001;73:517-525.
123. Schulman S. Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness. Semin Thromb Hemost. 2000;26:421-424.
124. Baudo F, Redaelli R, Caimi TM, et al. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. Thromb Res. 2000;99:21-24.
125. Ewenstein BM. Continuous infusion of recombinant factor VIIa: continue or not? Thromb Haemost. 2001;86:942-944.
126. Schulman S, Bech Jensen M, Varon D, et al. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost. 1996;75:432-436.
127. Stachnik JM, Gabay MP. Continuous infusion of coagulation factor products. Ann Pharmacother. 2002;36:882-891.
128. Santagostino E, Morfini M, Rocino A, et al. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost. 2001;86:954-958.
129. Hedner U. Dosing and monitoring NovoSeven treatment. Haemostasis. 1996;26(suppl 1):102-108.
130. Ingerslev J, Christiansen K, Calatzis A, et al. Management and monitoring of recombinant activated factor VII. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S25-S30.
131. Smith MP, Ludlam CA, Collins PW, et al. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/mL is associated with an increased incidence of bleeding. Thromb Haemost. 2001;86:949-953.
132. Johannessen M, Nielsen G, Nordfang O. Comparison of the factor VII:C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven). Blood Coagul Fibrinolysis. 2000;11(suppl 1):S159-S164.
133. Yoshioka A, Nishio K, Shima M. Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII. Haemostasis. 1996;26(suppl 1):39-142.
134. Cid AR, Lorenzo JI, Haya S, et al. A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment. Haemophilia. 2001;7:39-41.
135. Greisen G, Andreasen RB. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul Fibrinolysis. 2003;14:117-120.
136. Nicolaisen EM. Long-term follow-up with regard to potential immunogenicity: clinical experience with NovoSeven (recombinant factor VIIa). Haemostasis. 1996;26(suppl 1):98-101.
137. Roberts HR. Recombinant factor VIIa (Novoseven) and the safety of treatment. Semin Hematol. 2001;38(4 suppl 12):48-50.
138. Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor [letter]. Thromb Haemost. 1999;82:1775-1776.
139. Rosenfeld SB, Watkinson KK, Thompson BH, et al. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient [letter]. Thromb Haemost. 2002;87:925-926.
140. Aledort LM. Recombinant factor VIIa is a pan-hemostatic agent? [published correction appears in Thromb Haemost. 2000;84:523]. Thromb Haemost. 2000;83:637-638.
141. Aledort LM. Recombinant factor VIIa is a pan-hemostatic agent? [published correction appears in Thromb Haemost. 2000;84:523]. Thromb Haemost. 2000;83:637-638.
142. Ng H, Loh YSM, Ho LP, et al. Thrombotic events associated with the use of recombinant factor VIIa in a single institution: a role of caution [abstract]. J Thromb Haemost. 2003;1(suppl 1).
143. Kadayifcilar S, Ozatli D, Ozceba O, et al. Is activated factor VII associated with retinal vein occlusion? Br J Ophthalmol. 2001;85:1174-1178.
144. Poon MC. Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opin Hematol. 2001;8:312-318.